ProMIS Neurosciences Inc.

Good afternoon and welcome to the ProMIS Neurosciences Second Quarter 2026 Financial Results and Business Update Conference Call. All participants will be in a listen-only mode. Instructions for the question and answer session will be given following the pre-recorded remarks, prepared remarks. As a reminder, this conference is being recorded. I would now like to turn the call over to Carrie Pierce, Vice President, Investor Relations and External Affairs at ProMIS Neurosciences. Please go ahead.

Thank you, Operator, and good afternoon, everyone. Thank you for joining PROMIS Neurosciences' second quarter 2026 financial results and business update conference call. Presenting on our call today are Neil Warma, our President and Chief Executive Officer, and Dr. Larry Alstiel, our Chief Medical Officer. Earlier today, we filed our quarterly report on Form 10Q with the SEC for the quarter ended June 30, 2026, and issued a press release with our financial results. Both are available in the investor relations section of our website at promisedneurosciences.com. Before we begin, I would like to remind everyone that statements made on this call include forward-looking statements with the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, among others, statements regarding our clinical development plans and timelines for PMN 310, PMN 267, and PMN 442, and our other product candidates, the interpretation of the significance of the blinded interim data from our precise AD trial, our expectations regarding future clinical results, and our financial position in cash runway, and our overall business strategy. These forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. We encourage you to review the risk factors described in our most recent annual report on Form 10-K, are Form 10Q filed today and other filings with the SEC. We undertake no obligation to update or revise any forward-looking statements as a result of new information, future events, or otherwise, except as required by law. With that, I would like to turn the call over to Neil.

Thank you, Kerry. Welcome to all those who are joining us today to discuss PROMIS Neurosciences results for the second quarter of 2026 and also to review the recent progress across our pipeline. As Terry said, joining on the call today is Dr. Larry Alsteel, our Chief Medical Officer, who will walk us through the encouraging interim data we recently reported from our Phase 1b Precise AD clinical trial. I'll then provide a financial update before we open the line up for a few questions. As many of you know, PROMIS is a clinical stage biotechnology company applying our patented technology It's a platform to build a portfolio of antibody therapies and therapeutic vaccines for neurodegenerative diseases with a focus on Alzheimer's disease, dementia with Lewy bodies, ALS and Parkinson's. We believe these diseases share a common biological cause, normal proteins that misfold, become toxic and kill neurons. Our platform is designed to combine protein biology, physics, in supercomputing to selectively target these toxic misfolded proteins while sparing their healthy, properly folded counterparts. Our lead product candidate is PMN310, which is a monoclonal antibody designed to treat Alzheimer's disease by selectively targeting toxic misfolded oligomers of amyloid beta. Behind PMN310, we are advancing PMN267 for ALS, which targets misfolded TDP43, and PMN442 for synucleinopathies such as dementia with Lewy bodies and Parkinson's disease, which target pathogenic alpha-synuclein. Both PMN267 and 442 have been humanized in a human IgG1 framework and are advancing toward IND-enabling studies. We're also progressing a set of vaccine programs in Alzheimer's and Parkinson's and ALS. As we've recently discussed, the second quarter was a defining period for PROMIS. In late July, we reported positive blinded six-month interim safety and biomarker results from our ongoing Phase 1b precise AD clinical study of PMN310. Data we believe reinforced the core thesis behind our oligomer selective approach. Larry will walk us through the details in a moment, but at a high level, the blinded interim analysis yielded a favorable safety profile across all participants and genotypes, showing no cases of ARIA-E and early directionally consistent movement in two complementary biomarkers, plasma pTAU217 and CSF MTBR TAU243, which is consistent with target engagement. We believe these data reinforce the central thesis behind TMN310. that by selectively targeting toxic amyloid beta oligomers rather than plaque, we have the potential to deliver the benefits of amyloid-directed therapy without the aria burden that has constrained this class of medicines. We actually hosted a live webinar back on July 28th with two independent key opinion leaders, Dr. Will Monti, University of Minnesota, and Dr. Mike Weiner of UCSF, who shared their perspective on the data and its clinical relevance. And for those of you who missed it, the presentation and recording of the webinar are available archived on our website. And this, we believe, is truly the most meaningful clinical milestone in the company's history to date. I would now like to ask Dr. Alstil to walk through the precise AD summary of the interim data in a little bit more detail. Larry, if you would please.